Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivastigmine
Drug ID BADD_D01955
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D03822
MeSH ID D000068836
PubChem ID 77991
TTD Drug ID D0WY5Q
NDC Product Code 0378-9071; 51956-0001; 51956-0003; 70710-1198; 65162-826; 49706-1825; 51956-0002; 0078-0502; 72855-100; 0378-9070; 50379-0014; 65015-819; 46708-835; 51991-899; 0078-0503; 63629-8846; 65862-982; 65162-825; 72855-101; 63629-8807; 63629-2065; 65162-749; 51991-898; 0378-9072; 64552-4021; 0781-7313; 72855-102; 16714-117; 16714-116; 51991-897; 0781-7309; 70710-1196; 12651-118; 63629-2066; 0078-0501; 16714-115; 0781-7304; 65372-1153; 82245-0107; 63629-2064; 70710-1197
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C14H22N2O2
CAS Registry Number 123441-03-2
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AstheniaCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
DiarrhoeaCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
DizzinessCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
VomitingCholinesteraseP06276T9979911475943; 9880090; 16437532; 10090427
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.0030.004968%Not Available
Diarrhoea07.02.01.0010.022356%
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.0070.009936%
Duodenitis haemorrhagic24.07.02.025; 07.08.03.0100.000648%Not Available
Dyskinesia17.01.02.0060.002484%
Dyspepsia07.01.02.0010.003726%
Dystonia17.01.03.001--Not Available
Epistaxis24.07.01.005; 22.04.03.0010.002484%
Erythema23.03.06.0010.003726%Not Available
Fall12.01.08.002--
Fatigue08.01.01.0020.008694%
Feeling abnormal08.01.09.0140.004968%Not Available
Gait disturbance17.02.05.016; 08.01.02.0020.006210%
Gastritis07.08.02.0010.000648%
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.000648%Not Available
Haematemesis24.07.02.011; 07.12.02.0020.004968%Not Available
Hallucination19.10.02.0020.011178%
Hallucination, visual19.10.02.0040.004968%Not Available
Headache17.14.01.0010.008694%
Heart rate decreased13.14.04.0010.002484%Not Available
Hip fracture15.08.03.001; 12.04.01.0010.003726%
Hyperglycaemia14.06.02.002; 05.06.02.0020.002484%
Hyperhidrosis23.02.03.004; 08.01.03.0280.011178%
Hypertension24.08.02.0010.003726%
Hypokinesia17.01.02.009--Not Available
Hypotension24.06.03.0020.003726%
Insomnia17.15.03.002; 19.02.01.0020.002484%
Lacrimation increased06.08.02.0040.002484%
Liver function test abnormal13.03.01.013--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages